Home | A cure for a cost
In this issue
SHL Group Company Insight
Scandinavian Health
Contents
News
NSF
VEGA Company Insight
VEGA Australia
Covid-19 executive briefing by GlobalData
The value of real-world evidence during the Covid-19 outbreak
Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industry
Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concerns
AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19
Phoenix
Phoenix Company Insight
The pharma industry briefing
No time to waste: repurposing drugs to tackle covid-19
How safe are simple painkillers?
Molnar Company Insight
Molnar-Institute
Modelling the human body: a game changer for drug testing?
Pandemic pricing: existing drugs and price gouging
Contract Pharmaceuticals Limited Canada
Pandemic pricing: novel treatments and vaccines
The dark side of anticoagulants: will a new approach shed light?
Zenatek
Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill
Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issue
Nelson Labs
Could nanoparticles unlock the pharmaceutical benefits of turmeric?
Why aren’t more companies automating PV data capture?
Modality Solutions
Deals in brief powered by GlobalData
The key list powered by GlobalData
Butterworth
Global markets and indices powered by GlobalData
Macro-economic indicators (1 of 2) powered by GlobalData
Macro-economic indicators (2 of 2) powered by GlobalData
Mimotopes
Events
Next issue
05/27/2020 00:00:00
Go to article:
Home | A cure for a cost
Go to article:
In this issue
Go to article:
SHL Group Company Insight
Go to article:
Scandinavian Health
Go to article:
Contents
Go to article:
News
Go to article:
NSF
Go to article:
VEGA Company Insight
Go to article:
VEGA Australia
Go to article:
Covid-19 executive briefing by GlobalData
Go to article:
The value of real-world evidence during the Covid-19 outbreak
Go to article:
Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industry
Go to article:
Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concerns
Go to article:
AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19
Go to article:
Phoenix
Go to article:
Phoenix Company Insight
Go to article:
The pharma industry briefing
Go to article:
No time to waste: repurposing drugs to tackle covid-19
Go to article:
How safe are simple painkillers?
Go to article:
Molnar Company Insight
Go to article:
Molnar-Institute
Go to article:
Modelling the human body: a game changer for drug testing?
Go to article:
Pandemic pricing: existing drugs and price gouging
Go to article:
Contract Pharmaceuticals Limited Canada
Go to article:
Pandemic pricing: novel treatments and vaccines
Go to article:
The dark side of anticoagulants: will a new approach shed light?
Go to article:
Zenatek
Go to article:
Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill
Go to article:
Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issue
Go to article:
Nelson Labs
Go to article:
Could nanoparticles unlock the pharmaceutical benefits of turmeric?
Go to article:
Why aren’t more companies automating PV data capture?
Go to article:
Modality Solutions
Go to article:
Deals in brief powered by GlobalData
Go to article:
The key list powered by GlobalData
Go to article:
Butterworth
Go to article:
Global markets and indices powered by GlobalData
Go to article:
Macro-economic indicators (1 of 2) powered by GlobalData
Go to article:
Macro-economic indicators (2 of 2) powered by GlobalData
Go to article:
Mimotopes
Go to article:
Events
Go to article:
Next issue